Ibuprofen hepatic encephalopathy, hepatomegaly, gastric lesion and gastric pentadecapeptide BPC 157 in rats.

Ilic S, Drmic D, Zarkovic K, Kolenc D, Brcic L, Radic B, Djuzel V, Blagaic AB, Romic Z, Dzidic S, Kalogjera L, Seiwerth S, Sikiric P

European journal of pharmacology30 May 2011Cited by 51 (Europe PMC)

PMID21645505DOI10.1016/j.ejphar.2011.05.038PepBankPUB-21645505

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats given chronic ibuprofen, BPC‑157 counteracted hepatic encephalopathy.
In plain wordsIn rats given ibuprofen for weeks, BPC‑157 countered the brain damage from liver failure.
Peptide
BPC-157
Outcome
DecreaseHepatic encephalopathy
Study
ratn: not reported in source
Chronic ibuprofen toxicity (0.4 g/kg intraperitoneally, daily for 4 weeks)
Outcome group
Adverse events · Nervous system and cognition
Studied dose
10 µg/kg, 10 ng/kg (intraperitoneal); 0.16 µg/ml, 0.16 ng/ml (drinking water) · intraperitoneal or per-oral (drinking water)As given in this study (rat).
Source sentences
Summary
Counteracted were all adverse effects, such as hepatic encephalopathy, the gastric lesions, hepatomegaly, increased liver serum values.
1 context sentence(design, population, supporting numbers)
Summary · context
An anti-ulcer peptide shown to have no toxicity, the stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419, 10 μg, 10 ng/kg) inhibited the pathology seen with ibuprofen (i) when given intraperitoneally, immediately after ibuprofen daily or (ii) when given in drinking water (0.16 μg, 0.16 ng/ml).
Report a problemFND-2164550501
02AnimalAnimal study (in vivo)Efficacy outcome
In rats given chronic ibuprofen, BPC‑157 counteracted gastric lesions.
In plain wordsIn rats given ibuprofen for weeks, BPC‑157 countered stomach damage.
Peptide
BPC-157
Outcome
DecreaseGastric lesions
Study
ratn: not reported in source
Chronic ibuprofen toxicity (0.4 g/kg intraperitoneally, daily for 4 weeks)
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
10 µg/kg, 10 ng/kg (intraperitoneal); 0.16 µg/ml, 0.16 ng/ml (drinking water) · intraperitoneal or per-oral (drinking water)As given in this study (rat).
Source sentences
Summary
Counteracted were all adverse effects, such as hepatic encephalopathy, the gastric lesions, hepatomegaly, increased liver serum values.
1 context sentence(design, population, supporting numbers)
Summary · context
An anti-ulcer peptide shown to have no toxicity, the stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419, 10 μg, 10 ng/kg) inhibited the pathology seen with ibuprofen (i) when given intraperitoneally, immediately after ibuprofen daily or (ii) when given in drinking water (0.16 μg, 0.16 ng/ml).
Report a problemFND-2164550502
03AnimalAnimal study (in vivo)Efficacy outcome
In rats given chronic ibuprofen, BPC‑157 counteracted hepatomegaly.
In plain wordsIn rats given ibuprofen for weeks, BPC‑157 countered liver enlargement.
Peptide
BPC-157
Outcome
DecreaseHepatomegaly
Study
ratn: not reported in source
Chronic ibuprofen toxicity (0.4 g/kg intraperitoneally, daily for 4 weeks)
Outcome group
Liver fat and liver function · Liver
Studied dose
10 µg/kg, 10 ng/kg (intraperitoneal); 0.16 µg/ml, 0.16 ng/ml (drinking water) · intraperitoneal or per-oral (drinking water)As given in this study (rat).
Source sentences
Summary
Counteracted were all adverse effects, such as hepatic encephalopathy, the gastric lesions, hepatomegaly, increased liver serum values.
1 context sentence(design, population, supporting numbers)
Summary · context
An anti-ulcer peptide shown to have no toxicity, the stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419, 10 μg, 10 ng/kg) inhibited the pathology seen with ibuprofen (i) when given intraperitoneally, immediately after ibuprofen daily or (ii) when given in drinking water (0.16 μg, 0.16 ng/ml).
Report a problemFND-2164550503
04AnimalAnimal study (in vivo)Efficacy outcome
In rats given chronic ibuprofen, BPC‑157 counteracted the increased liver serum values.
In plain wordsIn rats given ibuprofen for weeks, BPC‑157 countered the rise in blood liver markers.
Peptide
BPC-157
Outcome
DecreaseLiver serum values (AST, ALT)
Study
ratn: not reported in source
Chronic ibuprofen toxicity (0.4 g/kg intraperitoneally, daily for 4 weeks)
Outcome group
Liver fat and liver function · Liver
Studied dose
10 µg/kg, 10 ng/kg (intraperitoneal); 0.16 µg/ml, 0.16 ng/ml (drinking water) · intraperitoneal or per-oral (drinking water)As given in this study (rat).
Source sentences
Summary
Counteracted were all adverse effects, such as hepatic encephalopathy, the gastric lesions, hepatomegaly, increased liver serum values.
2 context sentences(design, population, supporting numbers)
Summary · context
increased AST and ALT serum values with prolonged sedation/unconsciousness, and weight loss.
Summary · context
An anti-ulcer peptide shown to have no toxicity, the stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419, 10 μg, 10 ng/kg) inhibited the pathology seen with ibuprofen (i) when given intraperitoneally, immediately after ibuprofen daily or (ii) when given in drinking water (0.16 μg, 0.16 ng/ml).
Report a problemFND-2164550504
05AnimalAnimal study (in vivo)Safety outcome
In rats given chronic ibuprofen, BPC‑157-treated rats showed no behavioral disturbances.
In plain wordsIn rats given ibuprofen for weeks, rats treated with BPC‑157 showed no behavior problems.
Peptide
BPC-157
Outcome
No significant changeBehavioral disturbances
Study
ratn: not reported in source
Chronic ibuprofen toxicity (0.4 g/kg intraperitoneally, daily for 4 weeks)
Outcome group
Adverse events · Nervous system and cognition
Studied dose
10 µg/kg, 10 ng/kg (intraperitoneal); 0.16 µg/ml, 0.16 ng/ml (drinking water) · intraperitoneal or per-oral (drinking water)As given in this study (rat).
Source sentences
Summary
In addition, BPC 157 treated rats showed no behavioral disturbances and maintained normal weight gain.
1 context sentence(design, population, supporting numbers)
Summary · context
An anti-ulcer peptide shown to have no toxicity, the stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419, 10 μg, 10 ng/kg) inhibited the pathology seen with ibuprofen (i) when given intraperitoneally, immediately after ibuprofen daily or (ii) when given in drinking water (0.16 μg, 0.16 ng/ml).
Report a problemFND-2164550505
06AnimalAnimal study (in vivo)Efficacy outcome
In rats given chronic ibuprofen, BPC‑157-treated rats maintained normal weight gain, whereas ibuprofen alone caused weight loss.
In plain wordsIn rats given ibuprofen for weeks, rats treated with BPC‑157 kept normal weight gain, while ibuprofen alone caused weight loss.
Peptide
BPC-157
Outcome
IncreaseWeight gain
Study
ratn: not reported in source
Chronic ibuprofen toxicity (0.4 g/kg intraperitoneally, daily for 4 weeks)
Outcome group
Body weight · Metabolic and weight
Studied dose
10 µg/kg, 10 ng/kg (intraperitoneal); 0.16 µg/ml, 0.16 ng/ml (drinking water) · intraperitoneal or per-oral (drinking water)As given in this study (rat).
Source sentences
Summary
In addition, BPC 157 treated rats showed no behavioral disturbances and maintained normal weight gain.
2 context sentences(design, population, supporting numbers)
Summary · context
and weight loss.
Summary · context
An anti-ulcer peptide shown to have no toxicity, the stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419, 10 μg, 10 ng/kg) inhibited the pathology seen with ibuprofen (i) when given intraperitoneally, immediately after ibuprofen daily or (ii) when given in drinking water (0.16 μg, 0.16 ng/ml).
Report a problemFND-2164550506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 02:56 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.